TrialDiabetes, obesity & metabolism2018

Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial.

Jeremy Pettus et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.